Production Linked Incentive Schemes have Strengthened India’s Pharmaceutical, Bulk Drugs and Medical Devices Manufacturing Ecosystem
Cite this
Citations are auto-generated; verify before publishing. The analysis classification is PolicyDhara's, not the source's.
Research or analytical publication — an evidence-based assessment informing policy design and evaluation. Shapes the intellectual framework within which policy debates occur.
Summary
PLI Schemes are strengthening India’s pharmaceutical, bulk drugs and medical devices manufacturing ecosystem by supporting investment, domestic production, employment, exports and technology adoption.
Key Facts
TypeAnalysis
SourceIndia Brand Equity Foundation
PublishedMonday, 28 September 2026
Affected Population1.4 billion citizens, 5 million healthcare workers
Key Numbers
Health budget: Rs 90,958 crore (2025-26)
Target: 2.5% of GDP public health spending
1.5 lakh Health & Wellness Centres planned
GDP: $3.9 trillion (2025 est.)
Key Authorities
Key Stakeholders
Government Context
NDA IIIBJP-led NDA
LeftCentreRight
Impact Assessment
7/10
Impact ScoreBeneficiariesManufacturing sector — MSMEs and large enterprises
Budget AllocationRs 197K Crore
CoverageAll states and UTs
Implementation StatusOperational
60% implemented
Key Outcomes
- PLI schemes across 14 sectors with Rs 1.97 lakh crore outlay
- India's manufacturing share in GDP: 17.4% (target 25%)
- FDI inflows crossed $100 billion in 2024-25
Challenges
- Land acquisition delays
- Infrastructure gaps in hinterland
- Skill shortages